Primary results from IMfirst, a Phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain
Atezolizumab;Carboplatin;Cisplatin;Etoposide
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Primary results from IMfirst, a Phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain ### Output: Atezolizumab;Carboplatin;Cisplatin;Etoposide